For a patient with a history of lung cancer, how should the slight increase in size of a right upper‑lobe consolidation and the dilation of the main pulmonary artery be interpreted, and what follow‑up imaging and cardiac evaluation are indicated?

Interpretation of Imaging Findings in a Patient with Prior Lung Cancer

This imaging shows a growing right upper lobe consolidation that requires urgent PET/CT to distinguish between post-radiation changes and cancer recurrence, while the dilated pulmonary artery warrants echocardiographic evaluation for pulmonary hypertension.

Understanding the Consolidation Growth

The slight increase in consolidation size (from 7.0 x 3.5 x 2.9 cm to 7.3 x 4.3 x 3.3 cm) is concerning in a patient with prior lung cancer. While this could represent:

• Post-radiation atelectasis or fibrosis
• Superimposed infection
• Recurrent or residual malignancy (the most critical consideration)

The radiologist appropriately hedges because distinguishing these entities on CT alone is unreliable. Follow-up PET/CT is the recommended next step 1. The ACCP guidelines specifically recommend chest CT surveillance every 6 months for the first 2 years after curative-intent therapy, then annually 1. When CT findings are equivocal—as in this case where malignancy cannot be excluded—functional imaging with PET/CT becomes essential to detect metabolically active disease.

Clinical Decision Algorithm for the Consolidation

1. Order PET/CT within 2-4 weeks to assess for metabolically active disease
2. If PET shows increased FDG uptake (SUVmax significantly elevated):
   • Proceed to tissue diagnosis (CT-guided biopsy or bronchoscopy)
   • Consider this recurrent disease until proven otherwise
3. If PET shows minimal or no uptake:
   • Likely represents post-radiation changes or atelectasis
   • Continue surveillance CT in 3 months to document stability
4. The treating oncologist/surgeon must participate in this decision-making 1—radiologist interpretation alone is insufficient, as one study showed that two-thirds of "abnormal" surveillance scans were false alarms when radiologist reports were used in isolation 1

Interpreting the Pulmonary Artery Dilation

The main pulmonary artery diameter of 3.2 cm is abnormal and clinically significant. Research demonstrates that:

• Pulmonary artery enlargement is more prevalent in lung cancer patients than other cancer types 2
• PA dilation >2.9 cm in men or >2.7 cm in women predicts pulmonary hypertension 2
• PA enlargement is associated with worse postoperative outcomes and reduced overall survival in lung cancer patients 3, 4

This finding warrants cardiac evaluation with transthoracic echocardiography 5. The echo should specifically assess:

• Right ventricular size and function
• Estimated pulmonary artery systolic pressure
• Signs of right heart strain
• Left ventricular function

Why the Pulmonary Artery Matters

Several mechanisms could explain PA dilation in this patient:

• Tumor-related vascular obstruction (lung cancer can directly compress or invade pulmonary vessels) 6
• Chronic hypoxemia from underlying lung disease
• Radiation-induced vascular changes
• Thromboembolic disease (common in cancer patients)

The PA dilation has prognostic implications beyond immediate management—it's an independent predictor of worse cancer-specific survival 3. If pulmonary hypertension is confirmed, this affects:

• Surgical candidacy if further resection is needed
• Tolerance of systemic therapy
• Overall prognosis

Critical Pitfalls to Avoid

1. Do not assume the consolidation is benign just because it's only slightly larger—recurrent malignancy must be excluded with PET/CT
2. Do not ignore the PA dilation—this is not just an incidental finding but has both diagnostic and prognostic significance
3. Do not order surveillance imaging without involving the original treating physicians in interpretation 1—context matters enormously
4. Do not delay PET/CT—waiting months for "stability" risks missing early recurrence when it's still potentially treatable

Immediate Action Plan

Within 1-2 weeks:

• Order PET/CT for the consolidation
• Order transthoracic echocardiography for PA dilation assessment
• Review with the original treating oncologist/surgeon

Within 2-4 weeks:

• Multidisciplinary tumor board discussion incorporating PET/CT results
• If PET positive: tissue diagnosis
• If echo shows pulmonary hypertension: consider right heart catheterization for definitive diagnosis

The combination of these findings—growing consolidation plus PA dilation—suggests either disease progression or significant treatment-related complications, both requiring prompt evaluation to optimize outcomes.